Group 1 - The company plans to apply for the registration and issuance of medium-term notes not exceeding RMB 1 billion in the interbank bond market to improve financing efficiency and reduce costs [1][2] - The funds raised will be used for repaying financial institution loans, repaying maturing bonds, supplementing working capital, and other purposes compliant with regulations [1] - The issuance will be subject to market conditions and may be conducted in a single or multiple tranches within the validity period [1][2] Group 2 - The board of directors and the supervisory board have approved the issuance proposal, which will be submitted to the shareholders' meeting for approval and requires registration with the China Interbank Market Dealers Association [2] - The company will ensure compliance with relevant laws and regulations regarding the issuance and will disclose information on the progress of the medium-term note issuance [2]

Group 1 - The core viewpoint of the article highlights the financial performance of Lepu Medical in the first half of 2025, showing a slight decline in revenue and net profit, but an increase in cash flow from operating activities [1] - Lepu Medical achieved operating revenue of 3.369 billion yuan, a year-on-year decrease of 0.43% [1] - The net profit attributable to shareholders was 691 million yuan, down 0.91% year-on-year, while the net profit excluding non-recurring gains and losses was 662 million yuan, up 2.33% year-on-year [1] - The net cash flow from operating activities reached 636 million yuan, reflecting a significant increase of 300.52% [1] Group 2 - In terms of innovation, Lepu Medical's cardiovascular interventional product matrix is expected to contribute to revenue and profit growth, with several new products approved in the first half of the year [1] - Key new products include the Vessridge® coronary balloon dilation catheter, DilatBK™ paclitaxel-coated peripheral balloon dilation catheter, PeVaDilat™ drug-coated peripheral balloon dilation catheter, and FireZip® RF ablation device [1] - The company’s innovative drug subsidiary, Shanghai Minwei Biotechnology, has completed Phase II clinical trials for its GLP1/GCG/GIP receptor triple agonist candidate MWN101, marking a significant milestone in obesity and type 2 diabetes treatment [2] - Lepu Medical is advancing its consumer healthcare products in ophthalmology and dermatology, with new products approved for market [2] - The company has established marketing channels in over 160 countries and regions, with 341 product registrations covering various fields, demonstrating its commitment to internationalization [2]

Core Viewpoint - The company reported a slight decline in revenue and net profit for the reporting period, but showed significant improvement in cash flow from operating activities, indicating a potential for recovery and growth in the future [6]. Financial Performance - The company achieved operating revenue of 3,369.38 million yuan, a year-on-year decrease of 0.43% [6]. - The net profit attributable to shareholders was 690.93 million yuan, down 0.91% year-on-year [6]. - The net profit after deducting non-recurring gains and losses was 662.20 million yuan, reflecting a year-on-year increase of 2.33% [6]. - The net cash flow from operating activities was 636.36 million yuan, showing a substantial year-on-year increase of 300.52% [6]. - Total assets at the end of the reporting period were 25,358.93 million yuan, an increase of 3.20% from the beginning of the period [6]. - The net assets attributable to shareholders were 15,796.89 million yuan, up 3.92% from the beginning of the period [6]. - The weighted average return on net assets was 4.43% [6]. Business Segments Medical Devices - The medical device segment generated the highest revenue, totaling 1,776.47 million yuan, with a year-on-year growth of 1.30% [7]. - The cardiovascular interventional business achieved revenue of 1,238.60 million yuan, a year-on-year increase of 7.57%, with coronary intervention contributing 881.23 million yuan (up 3.60%) and structural heart disease generating 328.71 million yuan (up 32.06%) [7]. - The surgical anesthesia business reported revenue of 241.01 million yuan, down 10.29% year-on-year [8]. - The in-vitro diagnostics business had revenue of 163.37 million yuan, a year-on-year decline of 17.35% [9]. Pharmaceuticals - The pharmaceutical segment reported revenue of 1,117.44 million yuan, a year-on-year decrease of 1.52% but a quarter-on-quarter increase of 79.34% [10]. - The retail channel inventory clearance is nearly complete, with a gradual increase in the revenue share of non-atorvastatin calcium and clopidogrel [10]. - The generic drug segment achieved revenue of 975.35 million yuan, up 3.89% year-on-year, while the raw materials segment saw revenue of 142.10 million yuan, down 27.44% year-on-year [10]. Medical Services and Health Management - The medical services and health management segment generated revenue of 475.47 million yuan, a year-on-year decrease of 4.05% [11]. - The company provides cardiovascular disease medical services and health management through specialized hospitals and e-commerce platforms [11]. - The Hefei Cardiovascular Hospital reported revenue of 83.44 million yuan, an increase of 3.51% year-on-year [11]. - The AI-based health management services, focusing on cardiac monitoring and rehabilitation, generated revenue of 284.38 million yuan, reflecting a year-on-year growth of 8.64% [11].

Core Viewpoint - The company plans to change the purpose of repurchased shares from "employee stock ownership plan" to "reduce registered capital" and will seek shareholder approval for the cancellation of these shares [5][8]. Summary by Sections 1. Share Repurchase Plan Overview - In 2021, the company approved a share repurchase plan to buy back shares for employee stock ownership, with a maximum price of RMB 35 per share and a total fund of between RMB 30 million and RMB 50 million [1][2]. - By November 1, 2022, the company repurchased 18,273,500 shares, accounting for 0.9653% of the total share capital, with a total expenditure of RMB 355.78 million [2]. 2. Changes in Repurchase Plan - The company decided to terminate the 2022 restricted stock incentive plan due to unmet performance targets and stock price fluctuations [3]. - In 2023, a new repurchase plan was approved with a maximum price of RMB 25 per share and a total fund of between RMB 25 million and RMB 50 million [4]. 3. Change of Purpose for Repurchased Shares - The company intends to change the purpose of 37,215,700 repurchased shares to reduce registered capital, which will require shareholder approval [5][8]. - After the cancellation, the total share capital will decrease from 1,880,611,391 shares to 1,843,395,691 shares [5][7]. 4. Impact of Share Cancellation - The cancellation of repurchased shares is expected to enhance financial metrics such as earnings per share and net asset value without adversely affecting the company's operations or shareholder interests [8]. 5. Approval Process - The board of directors and the supervisory board have both approved the proposal to change the purpose of the repurchased shares and will seek shareholder approval for the necessary amendments to the company's articles of association [9].

证券代码：300003 证券简称：乐普医疗 公告编号：2025-074 乐普（北京）医疗器械股份有限公司 关于 2025 年半年度利润分配方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 乐普（北京）医疗器械股份有限公司（以下简称：公司）于 2025 年 8 月 21 日召开第六届董事会第十六次会议和第六届监事会第十一次会议，审议通过《关 于公司 2025 年半年度利润分配方案》的议案，该议案尚需提交公司 2025 年第 一次临时股东大会审议。现将有关内容公告如下： 一、利润分配方案基本情况 综合考虑公司的经营发展及广大投资者的利益等因素提出的，有利于广大投资者 分享公司发展的经营成果，与公司的经营业绩及未来发展相匹配。 二、相关风险提示 本次利润分配方案尚须提交公司股东大会审议批准后方可实施，该事项仍存 在不确定性，敬请广大投资者注意投资风险。 三、审议程序及相关意见 公司第六届董事会第十六次会议审议通过了《关于 2025 年半年度利润分配 方案》的议案，董事会认为：公司 2025 年半年度利润分配方案符合《公司法》 《公司章程》的规定，未损害公司 ...

（编辑 李家琪） 证券日报网讯 8月22日晚间，乐普医疗发布公告称，公司于2025年8月21日召开第六届董事会第十六次 会议，审议通过《关于使用募集资金置换预先投入募投项目自筹资金》的议案，同意公司以募集资金置 换预先投入募投项目的自筹资金，置换资金总额为人民币1，686.83万元。 ...

证券日报网讯 8月22日晚间，乐普医疗发布公告称，公司于2025年8月21日召开第六届董事会第十六次 会议和第六届监事会第十一次会议，审议通过了《关于使用部分闲置募集资金暂时补充流动资金》的议 案，同意公司在保证募集资金投资项目资金使用的前提下，使用闲置募集资金不超过人民币40，000万 元用于暂时补充流动资金，使用期限自董事会审议通过之日起不超过12个月，到期归还至募集资金专用 账户。 （编辑 李家琪） ...

Group 1 - The company, Lepu Medical, announced on August 22 that it will hold the 16th meeting of the 6th Board of Directors and the 11th meeting of the 6th Supervisory Board on August 21, 2025, to review the proposal for applying to register and issue medium-term notes [2] - The company aims to improve financing efficiency and rationally utilize different financing channels to reduce financing costs [2] - The company plans to apply for registration with the China Interbank Market Dealers Association and intends to publicly issue medium-term notes not exceeding RMB 1 billion (including 1 billion) in the national interbank bond market [2]

截至2025年8月22日收盘，乐普医疗股价报18.16元，较前一交易日下跌1.30%。当日成交额达7.35亿 元，成交量404968手，振幅2.28%。 乐普医疗是一家专注于心血管疾病领域的医疗健康企业，主要从事医疗器械、药品、医疗服务及健康管 理业务。公司产品涵盖心血管植介入器械、诊断试剂、药品等多个领域，形成了较为完整的产业链布 局。 公司8月22日披露的半年报显示，上半年实现营业收入33.69亿元，同比下降0.43%；归属于上市公司股 东的净利润6.91亿元，同比下降0.91%。公司拟向全体股东每10股派发现金红利1.6275元。报告期内， 心血管植介入业务实现营业收入12.39亿元，同比增长7.57%。公司同时公告拟申请注册发行不超过10亿 元中期票据。 8月22日乐普医疗主力资金净流出5674.13万元，近五日主力资金累计净流出7002.35万元。 风险提示：以上内容仅供参考，不构成任何投资建议。市场有风险，投资需谨慎。 来源：金融界 ...

Core Viewpoint - The CSI All Share Healthcare Equipment and Services Index has shown significant growth, reflecting a positive trend in the healthcare sector, with a notable increase in trading volume and index performance over various time frames [1][2]. Group 1: Index Performance - The CSI All Share Healthcare Equipment and Services Index rose by 0.14% to 15,554.17 points, with a trading volume of 35.351 billion [1]. - Over the past month, the index has increased by 10.85%, by 14.71% over the last three months, and by 13.47% year-to-date [1]. Group 2: Index Composition - The index comprises companies related to the healthcare theme, with the top ten weighted companies being Mindray Medical (9.17%), United Imaging (7.63%), Aier Eye Hospital (7.12%), and others [1]. - The index is primarily composed of companies listed on the Shenzhen Stock Exchange (59.89%) and the Shanghai Stock Exchange (40.11%) [1]. Group 3: Industry Representation - The index exclusively represents the healthcare sector, with a 100% allocation to pharmaceutical and healthcare-related companies [2]. - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2]. Group 4: Investment Products - Several public funds track the CSI All Share Healthcare Equipment and Services Index, including various Southern and Tianhong funds, as well as ETFs from different asset management companies [2].